Female-Specific Modifiers for Healthy Early Action in Cardiovascular Risk Trajectories

Cardiovascular disease is the leading cause of death in women, yet risk is systematicallyunderestimated and preventive interventions are often initiated too late. Women aredisproportionately affected by obesity, diabetes, and smoking, but they also derivegreater cardioprotective benefit from physical activity, reaching near‐maximal protectionat approximately half the exercise dose required in men. FEM‐HEART targets a criticalpre‐clinical window by testing whether a personalized app‐based intervention and asupervised face‐to‐face lifestyle program, both integrating tailored exercise, nutrition,and stress reduction, can improve early cardiovascular risk profiles in high‐risk womenduring the peri‐ and postmenopausal transition.In this prospective randomized controlled trial embedded in routine preventive care atSVS Gesundheitszentrum, 605 women will be randomized to a digital arm, a supervisedintervention arm, or an untreated control group. The study will evaluate whether digitaland supervised delivery formats differ in their ability to modify early cardiovasculartrajectories before overt disease onset.By targeting this modifiable pre‐clinical phase, FEM‐HEART shifts cardiovascularprevention from reactive care to proactive, sex‐specific risk reduction and lays thefoundation for scalable, woman‐centered prevention strategies.